Regional Vulnerability to Brain Metastases Reflects Structural, Metabolic and Genetic Organization of the Healthy Brain
Background: Brain metastases (BMs), the most common intracranial tumor, do not distribute uniformly throughout the brain, but instead preferentially localize to specific regions. Building on known associations with perfusion and the gray-white matter junction, we hypothesized that regional vulnerability to BMs also reflects the cellular and molecular organization of the healthy brain. Methods: In a discovery cohort of 1,406 patients, we generated a voxelwise map of BM distribution and compared it with normative atlases of brain microstructure, vasculature, metabolism, cell-type composition, and gene expression. Associations were tested for replication in an independent multicenter validation cohort of 1,209 patients. Results: In the discovery cohort, BM frequency was higher near the gray-white matter junction and in regions with greater cerebral perfusion, glucose metabolism, and mitochondrial density. At the cellular level, BM frequency was inversely related to astrocyte and microglial transcriptional signatures. Using normative gene expression maps derived from postmortem healthy brain tissue, we identified 17 genes spatially associated with BM vulnerability and specific to metastases relative to other intracranial lesion types. These associations replicated in the validation cohort. The immune checkpoint gene LAG3 ranked among the ten genes most positively associated with metastatic vulnerability across all genes tested (r = 0.40-0.45, p < 0.001). LAG3 expression was also elevated in peritumoral brain metastasis tissue relative to control brain tissue in an independent spatial transcriptomic dataset. Conclusions: These findings suggest that BM vulnerability reflects healthy brain organization and identify LAG-3, a clinically targetable immune checkpoint, as a candidate link between regional brain immune biology and metastatic colonization.
Authors
- Fabian Wolpert (ORCID: https://orcid.org/0000-0001-9024-8736)
- Nayan Lamba (ORCID: https://orcid.org/0000-0002-2598-6529)
- Ross MacFadyen
- Ayal Aaron Aizer (ORCID: https://orcid.org/0000-0002-8941-188X)
- Eric Karl Oermann (ORCID: https://orcid.org/0000-0002-1876-5963)
- Raymond Y. Huang (ORCID: https://orcid.org/0000-0001-7661-797X)
- Kenneth Bernstein (ORCID: https://orcid.org/0000-0001-9484-2601)
- Frederic L. W. V. J. Schaper (ORCID: https://orcid.org/0000-0001-5487-0923)
- Ariel Arias
- Marian Galovic (ORCID: https://orcid.org/0000-0002-2307-071X)
- Jay Patel (ORCID: https://orcid.org/0000-0002-8507-795X)
- Douglas Kondziolka
- Hesham M. Elhalawani (ORCID: https://orcid.org/0000-0001-9848-2623)
- Joseph I. Turner (ORCID: https://orcid.org/0009-0009-2423-3451)
- Michael E. Pacold (ORCID: https://orcid.org/0000-0003-3688-2378)
- Allen Y. Fu
- Michael Weller (ORCID: https://orcid.org/0000-0002-1748-174X)
- Aaron Y Schwieger
Institutions
- Harvard University (US)
- University of Zurich (CH)
- NYU Langone Health (US)
- University Hospital of Zurich (CH)
- Dana-Farber Cancer Institute (US)
- Athinoula A. Martinos Center for Biomedical Imaging (US)
- Dana-Farber Brigham Cancer Center (US)
- Mass General Brigham (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-09
- DOI
- https://doi.org/10.64898/2026.11.06.26367469
- Primary Topic
- Brain Metastases and Treatment
- Type
- preprint